Skip to main content
. 2010 Nov 4;5(11):e13834. doi: 10.1371/journal.pone.0013834

Figure 6. The combination treatment of retinoic acids and/or SL142 or SL325 increased Bax protein expression and the promoter activity in H441 lung cancer cells.

Figure 6

A. Immunoblot analysis of RARα, RARβ, RXRα and RXRβ expressions after retinoic acids and/or SL142 or SL325 treatment in H441 lung cancer cells. Human lung cancer cells were harvested 24 hours after treatment with ATRA or 9-cis RA (2.5 µM) or/and SAHA, SL142 or SL325 (0.5 µM). β-actin is shown as control. B. Transient transfection reporter assays in H441 cells with pGL4. or pGL4.Bax (2 µg), plus pCMV. β-galactosidase (2 µg) after retinoic acids (2.5 µM) and/or SL142 or SL325 (0.5 µM) retinoic acids treatment. Results are indicated as Fig. 6A. *, significant difference from the promoter activity generated by pGL4.Bax after ATRA or 9-cis RA (2.5 µM) or SAHA, SL142 or SL325 (0.5 µM) (p<0.05).